A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

July 21, 2026 updated by: Incyte Corporation

A Phase 3, Randomized, Double-Blind, Efficacy, and Safety Study of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to < 12 years old) with nonsegmental vitiligo.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
250

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Incyte Corporation Call Center (US)
  • Phone Number: 1.855.463.3463
  • Email: medinfo@incyte.com

Study Contact Backup

  • Name: Incyte Corporation Call Center (ex-US)
  • Phone Number: +800 00027423
  • Email: eumedinfo@incyte.com

Study Locations

  • Argentina
      • Buenos Aires, Argentina, C1181ACH
        • Recruiting
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, Argentina, C1425BEA
        • Recruiting
        • Instituto de Neumonología Y Dermatología
      • Buenos Aires, Argentina, 01425
        • Recruiting
        • Psoriahue
      • Buenos Aires, Argentina, C1426ABP
        • Recruiting
        • Consultorios Médicos Dr. Doreski
      • Buenos Aires, Argentina, C1426
        • Recruiting
        • Derma Internacional S.A.
      • Derqui-pilar, Argentina, B16290DT
        • Recruiting
        • Hospital Universitario Austral
      • Mar del Plata, Argentina, B7600FYK
        • Recruiting
        • Centro de Investigaciones Médicas Mar del Plata
      • San Miguel de Tucumán, Argentina, 04000
        • Recruiting
        • Hospital del Nino Jesus
  • Austria
      • Graz, Austria, 08036
        • Recruiting
        • Universitaetsklinikum Graz
      • Innsbruck, Austria, 06020
        • Recruiting
        • Medical University Innsbruck
  • Belgium
      • Brussels, Belgium, 01070
        • Recruiting
        • Hopital Universitaire de Bruxelles (Academisch Ziekenhuis Brussel)
      • Ghent, Belgium, 09000
        • Recruiting
        • Universitair Ziekenhuis Gent
      • Leuven, Belgium, 03000
        • Recruiting
        • Universitair Ziekenhuis Leuven
      • Woluwe-Saint-Lambert, Belgium, 01200
        • Recruiting
        • Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc
  • Bulgaria
      • Dupnitsa, Bulgaria, 02600
        • Recruiting
        • Medical Center Asklepii OOD
      • Gabrovo, Bulgaria, 05300
        • Recruiting
        • MHAT Dr. Tota Venkova AD
      • Sevlievo, Bulgaria, 05400
        • Recruiting
        • Medical Center Unimed EOOD
      • Sofia, Bulgaria, 01528
        • Recruiting
        • 28 Diagnostic and Consultative Center
      • Sofia, Bulgaria, 01606
        • Recruiting
        • Mc Euroderma Clinic
      • Sofia, Bulgaria, 01618
        • Recruiting
        • Diagnostic Consultation Center Xx - Sofia Eood
      • Sofia, Bulgaria, 01431
        • Recruiting
        • UMHAT Aleksandrovska
  • Denmark
      • Hellerup, Denmark, 02900
        • Recruiting
        • Herlev and Gentofte Hospital
      • Herlev, Denmark, 02730
        • Recruiting
        • Sanos Clinic
  • France
      • Argenteuil, France, 95107
        • Recruiting
        • Centre Hospitalier Victor Dupouy
      • Bordeaux, France, 33076
        • Recruiting
        • Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin
      • Créteil, France, 75571
        • Recruiting
        • Centre Hospitalier Intercommunal De Creteil
      • Lyon, France, 69003
        • Recruiting
        • Hospices Civils de Lyon (Hcl) - Hopital Edouard Herriot (Heh)
      • Nantes, France, 44093
        • Recruiting
        • Centre Hospitalier Universitaire de Nantes (Chu de Nantes) - Hopital Hotel Dieu
      • Nice, France, 06200
        • Recruiting
        • Centre Hospitalier Universitaire de Nice,Hopital L Archet
      • Paris, France, 75015
        • Recruiting
        • Hôpital Universitaire Necker Enfants Malades
      • Reims, France, 51100
        • Not yet recruiting
        • Polyclinique de Courlancy
      • Toulouse, France, 31059
        • Recruiting
        • Centre Hospitalier Universitaire (CHU) de Toulouse - Hopital Larrey
      • Vandœuvre-lès-Nancy, France, 54500
        • Recruiting
        • Chu Nancy
  • Germany
      • Berlin, Germany, 10117
        • Recruiting
        • Charite - Universitaetsmedizin Berlin - Campus Charite Mitte (CCM)
      • Erlangen, Germany, 91054
        • Recruiting
        • Hautklinik Universitatsklinikum Erlangen
      • Hamburg, Germany, 22149
        • Recruiting
        • Katholisches Kinderkrankenhaus Wilhelmstift
      • Kiel, Germany, 24105
        • Recruiting
        • University Medical Center Schleswig-Holstein
      • Leipzig, Germany, 04103
        • Recruiting
        • Universitaetsklinikum Leipzig
      • Mainz, Germany, 55131
        • Recruiting
        • Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
      • München, Germany, 81675
        • Recruiting
        • Klinikum Rechts Der Isar Der Technischen Universitaet Muenchen (Hopital Rechts Der Isar)
      • Münster, Germany, 48149
        • Recruiting
        • University Hospital Muenster
  • Hungary
      • Budapest, Hungary, 01033
        • Recruiting
        • Clinexpert
      • Debrecen, Hungary, 04032
        • Recruiting
        • Debreceni Egyetem Klinikai Kozpon Belgyogy Klinika
      • Pécs, Hungary, 07632
        • Recruiting
        • University of Pecs-Clinical Center
      • Szeged, Hungary, 06720
        • Recruiting
        • University of Szeged
  • Italy
      • Bologna, Italy, 40138
        • Recruiting
        • A.O. Policlinico Sant'Orsola Malpighi-Universita Degli Studi Di Bologna
      • Brescia, Italy, 25123
        • Recruiting
        • Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia
      • Catania, Italy, 95123
        • Recruiting
        • Azienda Ospedaliero-Universitaria Policlinico Vittorio Emanuele Ospedale Gaspare Rodolico Di Catania
      • Milan, Italy, 20122
        • Recruiting
        • Uoc Dermatologia Ospedale Maggiore Policlinico, Fondazione Irccs Ca' Granda
      • Naples, Italy, 80131
        • Recruiting
        • Azienda Ospedaliero Universitaria Federico II di Napoli
      • Padua, Italy, 35100
        • Recruiting
        • Azienda Ospedale Università di Padova
      • Roma, Italy, 00167
        • Recruiting
        • Istituto Di Ricovero E Cura A Carattere Scientifico (Ircss)
      • Rome, Italy, 00137
        • Recruiting
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      • Rome, Italy, 00165
        • Not yet recruiting
        • IRCCS Ospedale Pediatrico Bambino Gesu
  • Netherlands
      • Amsterdam, Netherlands, 1105 AZ
        • Recruiting
        • Amsterdam Umc Research Bv
  • Poland
      • Gdansk, Poland, 80-546
        • Recruiting
        • Centrum Badań Klinicznych PI-House sp. z o.o.
      • Katowice, Poland, 40-568
        • Recruiting
        • Care Clinic Sp. Z O.O.
      • Krakow, Poland, 31-559
        • Recruiting
        • Diamond Clinic Specjalistyczne Poradnie Lekarskie
      • Lublin, Poland, 20-607
        • Recruiting
        • DERMEDIC Iwona Zdybska
      • Nowa Sól, Poland, 67-100
        • Recruiting
        • Twoja Przychodnia - Medyczne Nowa Sol
      • Osielsko, Poland, 86-031
        • Recruiting
        • Dermodent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski
      • Rzeszów, Poland, 35-055
        • Recruiting
        • Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie
      • Szczecin, Poland, 71-500
        • Recruiting
        • Twoja Przychodnia SCM
      • Warsaw, Poland, 02-625
        • Recruiting
        • Evimed Sp. Z O. O.
  • Portugal
      • Coimbra, Portugal, 3000-075
        • Recruiting
        • Centro Hospitalar E Universitario Coimbra
      • Lisbon, Portugal, 1169-050
        • Recruiting
        • Centro Hospitalar de Lisboa Central - Hospital Santo Antonio Dos Capuchos
      • Porto, Portugal, 4099-001
        • Recruiting
        • Hospital Geral de Santo Antonio
  • Spain
      • Alcorcón, Spain, 28922
        • Recruiting
        • Hospital Universitario Fundacion Alcorcon
      • Badalona, Spain, 08916
        • Recruiting
        • Hospital Universitari Germans Trias i Pujol
      • Barcelona, Spain, 08026
        • Recruiting
        • Hospital De La Santa Creu I Sant Pau
      • Esplugues de Llobregat, Spain, 08950
        • Recruiting
        • Hospital Sant Joan de Déu Barcelona
      • Madrid, Spain, 28009
        • Recruiting
        • Hospital Infantil Unversitario Nino Jesus
      • Zaragoza, Spain, 50009
        • Recruiting
        • Hospital Universitario Miguel Servet de Zaragoza
  • United Kingdom
      • Croydon, United Kingdom, CR7 7YE
        • Not yet recruiting
        • Croydon University Hospital
      • London, United Kingdom, SE1 9RT
        • Not yet recruiting
        • Guys Hospital
      • London, United Kingdom, WC1N 3JH
        • Not yet recruiting
        • Great Ormond Street Hospital for Children NHS Foundation Trust
      • London, United Kingdom, E1 1FR
        • Recruiting
        • The Royal London Hospital - Barts Health Nhs Trust
      • Sheffield, United Kingdom, S10 2TH
        • Recruiting
        • Sheffield Childrens Hospital
      • Walsall, United Kingdom, WS2 9PS
        • Not yet recruiting
        • Manor Hospital (Walsall) - Walsall Healthcare Nhs Trust

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Aged 6 to < 12 years at the time of signing the ICF.
  • Clinical diagnosis of nonsegmental vitiligo with depigmented area including ≥ 0.5% BSA on the face, ≥ 0.5 F-VASI, ≥ 3% BSA on nonfacial areas, ≥ 3 T-VASI.
  • Total body vitiligo area does not exceed 10% BSA.
  • Pigmented hair within some of the areas of vitiligo on the face.
  • Must agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit.
  • For sexually active participants (except participants who are prepubescent) willingness to avoid pregnancy or fathering a child as defined in the protocol.

Exclusion Criteria:

  • Diagnosis of other forms of vitiligo (eg, segmental).
  • Other differential diagnosis of vitiligo or other skin depigmentation disorders (eg, piebaldism, pityriasis alba, leprosy, postinflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma, and tinea versicolor).
  • Any other skin disease that, in the opinion of the investigator, would interfere with the study drug application or study assessments.
  • Prior or current use of depigmentation treatments (eg, monobenzone).
  • Concurrent conditions and history of protocol-defined diseases
  • Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study, including application of study cream and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  • Use of protocol-defined treatments within the indicated washout period before baseline.
  • History of treatment failure with any systemic or topical JAK inhibitor for vitiligo or any other inflammatory condition.
  • Protocol-defined clinically significant abnormal laboratory values at screening.
  • BMI-for-age < 5th percentile or ≥ 85th percentile according to the CDC BMI Percentile Calculator for Child and Teen.
  • Pregnant or lactating participants or those considering pregnancy during the period of their study participation.
  • In the opinion of the investigator, unable or unlikely to comply with the application schedule and study evaluations.
  • Living with anyone participating in any current Incyte-sponsored ruxolitinib cream study.
  • Employees of the sponsor or investigator or are otherwise dependents of them.
  • Known allergy or reaction to any component of the study cream formulation.
  • The following participants are excluded in France: vulnerable populations according to article L.1121-6 of the French Public Health Code and adults under legal protection, or who are unable to express their consent per article L.1121-8 of the French Public Health Code, not affiliated to a social security per article L.1121-8-1 of the French Public Health code.
  • In the EU, participants considered incapacitated according to EU CTR No. 536/2014 Articles 2 and 31.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Ruxolitinib 1.5 % Cream
Participants received ruxolitinib 1.5% cream, applied topically to the affected area as defined in the protocol.
Drug: Ruxolitinib Cream
Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
Other Names:
  • INCB018424 Phosphate Cream
Placebo Comparator: Vehicle Cream
Participants received vehicle cream, applied topically to the affected area as defined by the protocol.
Drug: Vehicle Cream
Matching vehicle cream applied topically to the affected area as a thin film twice daily.
Experimental: Ruxolitinib 0.75 % Cream
Participants received ruxolitinib 0.75% cream, applied topically to the affected area as defined in the protocol.
Drug: Ruxolitinib Cream
Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
Other Names:
  • INCB018424 Phosphate Cream

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75)
Time Frame: Week 24
≥75% improvement in facial Vitiligo Area Scoring Index.
Week 24

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Proportion of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI50)
Time Frame: Week 24
≥50% improvement in facial Vitiligo Area Scoring Index.
Week 24
Proportion of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI90)
Time Frame: Week 24
≥90% improvement in facial Vitiligo Area Scoring Index.
Week 24
Proportion of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50)
Time Frame: Week 24
≥50% improvement in total body Vitiligo Area Scoring Index.
Week 24
Percentage change from baseline in F-BSA
Time Frame: Week 24
Facial body surface area (F-BSA) takes into account the facial depigmented areas as a percentage of the total body area.
Week 24
Number of Treatment Emergent Adverse Events (TEAEs)
Time Frame: Up to Week 52 and 30 days
TEAE defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.
Up to Week 52 and 30 days
Pharmacokinetic (PK) of Ruxolitinib: Trough concentrations
Time Frame: Weeks 6, 24, 30 and 52
Trough is defined as the concentration reached by a drug immediately before the next dose is administered.
Weeks 6, 24, 30 and 52
Proportion of participants achieving a Vitiligo Noticeability Scale (VNS) score of 4 (a lot less noticeable) or 5 (no longer noticeable)
Time Frame: Week 24 and Week 52
The VNS is a patient-reported measure of vitiligo treatment success that has a 5-point scale.
Week 24 and Week 52
Proportion of participants in each category for the color-matching question
Time Frame: Week 24 and Week 52
The color-matching question is a patient-reported measure of vitiligo treatment success that has a 5-point scale.
Week 24 and Week 52
Proportion of participants who report facial assessment of Patient Global Impression of Change-Vitiligo (F-PaGIC-V) of very much improved or much improved
Time Frame: Week 24 and Week 52
The F-PaGIC-V is an assessment of improvement by the participant that has a 7-point scale.
Week 24 and Week 52
Proportion of participants who report total body assessment of Patient Global Impression of Change-Vitiligo (T-PaGIC-V) of very much improved or much improved
Time Frame: Week 24 and Week 52
The T-PaGIC-V is an assessment of improvement by the participant that has a 7-point scale.
Week 24 and Week 52
Change from baseline in Psychosocial Impact Questionnaire for Pediatric Patients Who Have Nonsegmental Vitiligo (VIT-PIQ)
Time Frame: Week 24 and Week 52
The VIT-PIQ is a 17-item questionnaire to assess Quality of Life (QOL) of children with vitiligo.
Week 24 and Week 52
Change from baseline in Children's Dermatology Life Quality Index (CDLQI)
Time Frame: Week 24 and Week 52
The CDLQI is the youth/children's version of the Dermatology Life Quality Index.
Week 24 and Week 52
Change from baseline in Patient Global Impression of Bother - Vitiligo (PGIB-V)
Time Frame: Week 24 and Week 52
The PGIB-V is a single question with an 11-point scale ("not at all" to "a whole lot") to assess the participant's level of bother because of their vitiligo.
Week 24 and Week 52
Mean satisfaction score
Time Frame: Week 24 and Week 52
The treatment satisfaction tool is a fit-for-purpose questionnaire to assess treatment satisfaction in children with nonsegmental vitiligo.
Week 24 and Week 52

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Incyte Corporation

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Incyte Medical Monitor, Incyte Corporation

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 13, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 30, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 27, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 27, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 3, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 22, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 21, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • INCB18424-309
  • 2024-513171-41-00 (Registry Identifier: EU CT Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

IPD Sharing Time Frame

Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

IPD Sharing Access Criteria

Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings